Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 11:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–36 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Datopotamab Deruxtecan Clear all
Recruiting Phase 1Phase 2 Interventional

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

NCT05417594
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Recruiting Phase 3 Interventional

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Osimertinib, Datopotamab Deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
37
States / cities
Fountain Valley, California • Los Alamitos, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
58
States / cities
Daphne, Alabama • Prescott, Arizona • Jonesboro, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Active, not recruiting Phase 3 Interventional

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

NCT05555732
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
36
States / cities
Daphne, Alabama • Chandler, Arizona • Prescott Valley, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

NCT06564844
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan, Rilvegostomig, Carboplatin, Cisplatin, Etoposide, Pemetrexed, Vinorelbine, UFT
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Tucson, Arizona • Duarte, California • Glendale, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

NCT03944772
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 9, 2026, 11:15 AM EDT
Active, not recruiting Phase 3 Interventional

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

NCT05687266
View directory record Official record
Conditions
NSCLC
Interventions
Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin, Pemetrexed, Paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Recruiting Phase 3 Interventional

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Datopotamab deruxtecan (Dato-DXd), Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
51
States / cities
Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Recruiting Phase 2 Interventional

PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

NCT07069595
View directory record Official record
Conditions
Breast Cancer, Residual Disease, Triple Negative Breast Cancer (TNBC), Stage II/III
Interventions
Datopotamab deruxtecan, Circulating tumor DNA (ctDNA) testing
Drug · Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

NCT04484142
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
DS-1062a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
28
States / cities
Phoenix, Arizona • La Jolla, California • Santa Monica, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Active, not recruiting Phase 1 Interventional

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

NCT04526691
View directory record Official record
Conditions
Advanced or Metastatic NSCLC
Interventions
Datopotamab deruxtecan, KEYTRUDA®, Carboplatin, Cisplatin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • Duarte, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

NCT06244485
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Valemetostat tosylate, T-DXd, Dato-DXd
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
17
States / cities
Irvine, California • San Diego, California • Plantation, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 9, 2026, 11:15 AM EDT